awmsg logo



rucaparib (Rubraca®)


Reference No. 2473

Publication date:
06/11/2018


Appraisal information

rucaparib (Rubraca®) 250 mg film-coated tablet
rucaparib (Rubraca®) 300 mg film-coated tablet


Company: Clovis Oncology Inc
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 02/11/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, rucaparib (Rubraca®) cannot be endorsed for use within NHS Wales as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.
Statement of Advice (SOA)
Download